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he spliceosomal small nuclear RNAs (snRNAs) are
distributed throughout the nucleoplasm and concen-
trated in nuclear inclusions termed Cajal bodies
(CBs). A role for CBs in the metabolism of snRNPs has been
proposed but is not well understood. The SART3/p110
protein interacts transiently with the U6 and U4/U6 snRNPs
and promotes the reassembly of U4/U6 snRNPs after splicing
in vitro. Here we report that SART3/p110 is enriched in
CBs but not in gems or residual CBs lacking coilin. The U6
snRNP Sm-like (LSm) proteins, also involved in U4/U6
snRNP assembly, were localized to CBs as well. The levels
of SART3/p110 and LSm proteins in CBs were reduced
T
 
upon treatment with the transcription inhibitor 
 
 
 
-amanitin,
suggesting that CB localization reﬂects active processes
dependent on transcription/splicing. The NH
 
2
 
-terminal
HAT domain of SART3/p110 was necessary and sufﬁcient
for speciﬁc protein targeting to CBs. Overexpression of
truncation mutants containing the HAT domain had dominant
negative effects on U6 snRNP localization to CBs, indicating
that endogenous SART3/p110 plays a role in targeting the
U6 snRNP to CBs. We propose that U4 and U6 snRNPs
accumulate in CBs for the purpose of assembly into U4/U6
snRNPs by SART3/p110.
 
Introduction
 
The cell nucleus contains numerous, morphologically distinct
domains and bodies. One of these, a 0.5–1.0-
 
 
 
m sphere
named the Cajal body (CB),* was discovered 100 yr ago by
Santiago Ramón y Cajal. The molecular characterization of
CBs has been facilitated by the discovery of the protein coilin,
 
an unambiguous marker of CBs in 
 
Xenopus
 
, mouse, and
human cells (Raska et al., 1990, 1991; Andrade et al., 1991;
Tuma et al., 1993). Coilin likely plays an important role in
cell metabolism because coilin knockout mice exhibit reduced
viability (Tucker et al., 2001). Many factors involved in
transcription, RNA processing, and cell cycle regulation are
concentrated in CBs, but the function of CBs, with respect
to these diverse processes, remains obscure (Matera, 1999;
Gall, 2000). Although spliceosomal U1, U2, U4, U5, and
U6 small nuclear RNAs (snRNAs) are enriched in CBs
(Carmo-Fonseca et al., 1991, 1992; Matera and Ward,
1993), CBs are not likely sites of splicing because they are
not transcriptionally active and lack many essential non-snRNP
splicing factors (Matera, 1999; Raska et al., 1991). snRNP
association with CBs is transcription dependent, indicating
that CBs play an active role in snRNP metabolism and may
be the sites of snRNP assembly rather than storage of inactive
snRNPs (Carmo-Fonseca et al., 1992; Ogg and Lamond,
2002). What essential function accounts for the concentration
of spliceosomal snRNPs in CBs?
The U1, U2, U4, and U5 snRNAs are synthesized by
RNA polymerase II, capped at their 5
 
 
 
 ends, and transported
to the cytoplasm where they are bound by snRNP-specific
Sm proteins (for reviews see Will and Luhrmann, 2001;
Paushkin et al., 2002). These snRNAs are hypermethylated
 
at their 5
 
 
 
 ends, producing their characteristic 2,2,7 trimethyl-
guanosine (TMG) caps and providing an important signal
for snRNP import into the nucleus (Hamm et al., 1990).
Because snRNP-specific proteins appear to concentrate in
CBs before accumulating in the nucleoplasm, a role for CBs
in the maturation of snRNPs has been proposed (Sleeman
and Lamond, 1999; Sleeman et al., 2001; Ogg and Lamond,
2002). The recent identification of RNAs that guide base
modification of snRNAs and localization of these guide
RNAs to CBs suggest that snRNA base modification may
take place in CBs (Carmo-Fonseca, 2002; Darzacq et al.,
2002; Kiss, 2002; Kiss et al., 2002). However, these results
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do not explain why the U6 snRNA, which is synthesized by
RNA polymerase III, is not capped or exported to the cyto-
plasm, and undergoes base modification in the nucleolus
(Tycowski et al., 1998; Ganot et al., 1999; Lange and Gerbi,
2000), is present in CBs. The U6 snRNA is present in at
least three distinct snRNPs, the U6 snRNP, the U4/U6 sn-
RNP, and the U4/U6•U5 tri-snRNP. Formation of all of
these snRNP species must occur in the nucleus, but little is
known about the subnuclear location of these processes.
After assembly, the U1, U2, and U4/U6•U5 snRNPs per-
form essential functions in spliceosome formation and catal-
ysis. During a process termed the spliceosomal cycle, each
snRNP is thought to participate in subsequent rounds of
splicing, which then requires the regeneration of snRNPs
that have undergone rearrangement during splicing (Staley
and Guthrie, 1998). In particular, the U4/U6 snRNP,
which contains two snRNAs base paired with each other,
unwinds during splicing as U6 establishes new base-pairing
interactions with U2 and the pre-mRNA. Therefore, U4
and U6 must reanneal after splicing to regenerate functional
U4/U6 snRNPs. In yeast, the essential protein Prp24 cata-
lyzes this reaction (Raghunathan and Guthrie, 1998; Rader
and Guthrie, 2002). In the absence of Prp24p, splicing ex-
tracts are depleted of the U4/U6 snRNP, demonstrating the
importance of snRNP recycling for continuing rounds of
pre-mRNA splicing (Raghunathan and Guthrie, 1998).
Recently, the tumor rejection antigen SART3/p110 was
identified as the human homologue of Prp24p (Bell et al.,
2002; Rader and Guthrie, 2002) and was shown to be re-
quired for U4/U6 snRNP recycling in vitro (Bell et al.,
2002). SART3/p110 binds specifically and directly to the
U6 snRNA and is detectable in the U6 and U4/U6 snRNPs
(Bell et al., 2002). Unlike other U4, U5, and U6 snRNP–
specific proteins, SART3/p110 is not detectable in the U4/
U6•U5 tri-snRNP (Bell et al., 2002; Schneider et al.,
2002), indicating that SART3/p110 dissociates from its U4
and U6 snRNP substrates once they are annealed. In addi-
tion to SART3/p110, the Sm-like (LSm) proteins LSm2–8,
which assemble on the 3
 
 
 
 end of the U6 snRNA as a stable
heteromer and persist in the U4/U6 and U4/U6•U5 sn-
RNPs (Seraphin, 1995; Gottschalk et al., 1999; Salgado-
Garrido et al., 1999; Vidal et al., 1999; Schneider et al.,
2002), have been implicated in U4/U6 snRNP assembly
(Achsel et al., 1999; Mayes et al., 1999). The LSm proteins
bind directly to Prp24 in yeast (Fromont-Racine et al.,
2000; Rader and Guthrie, 2002; Ryan et al., 2002), provid-
ing a second mode of interaction with the U6 snRNP. In
vitro, Prp24p anneals U4 and U6 snRNAs more efficiently
in the context of snRNPs (Raghunathan and Guthrie,
1998), making it likely that the combination of SART3/
p110/Prp24p and LSm proteins enables efficient assembly
of the U4/U6 snRNP in vivo. Because the role of SART3/
p110 in U4/U6 recycling is uniquely transient, the subnu-
clear distribution of SART3/p110 has the potential to re-
veal the sites of U4/U6 snRNP assembly.
In this study, we report that SART3/p110 and the LSm
proteins, LSm4 and LSm8, are localized in the cell nucleus
and concentrated in CBs. We studied the association of
SART3/p110 and snRNPs with CBs after transcription in-
hibition and run-on treatment and in the absence of the CB
component coilin. SnRNP and SART3/p110 localizations
in CBs were correlated in each of these experimental condi-
tions. Mutant analysis revealed that the HAT domain of
SART3/p110 represents the major determinant for specific
targeting of SART3/p110 to CBs. Overexpression of mu-
tants lacking the snRNP-binding COOH-terminal domains
reduced the concentration of both endogenous SART3/
p110 and LSm4 in CBs, suggesting that SART3/p110 is re-
quired for U6 snRNP targeting to CBs.
 
Results
 
By immunofluorescent labeling of HeLa cells, SART3/p110
was detected exclusively in the cell nucleus, where it was dis-
tributed throughout the nucleoplasm and specifically en-
riched in large bright dots (Fig. 1, A and B). Double labeling
of cells for SART3/p110 and the TMG cap (Fig. 1 A), a
modification found at the 5
 
 
 
 end of U1, U2, U4, and U5
snRNAs, revealed complete overlap between SART3/p110
Figure 1. SART3/p110 is concentrated in CBs. (A and B) Immuno-
localization of SART3/p110 in HeLa cells together with (A) TMG 
cap, a marker of snRNPs, or (B) with coilin, a marker of CBs. 
(C) SART3/p110 and coilin were immunolocalized in human primary 
fibroblasts WI-38. CBs are marked by arrowheads. Bar, 5  m.T
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and snRNPs in the large bright structures. These bodies
were identified as CBs by double detection of SART3/p110
and coilin, a marker of CBs (Fig. 1 B). SART3 was detected
in all observed CBs (
 
n
 
 
 
 
 
 51 cells). The same results were ob-
tained in cells transiently expressing SART3/p110 conju-
gated to EGFP (see below and Fig. 7). Measurement of en-
dogenous SART3/p110 fluorescent intensities in CBs
revealed that the concentration of SART3/p110 in CBs is
approximately three times higher then in the nucleoplasm
(see below, Table I). We confirmed the SART3/p110 local-
ization patterns in WI-38 primary human fibroblasts (Fig. 1
C). Although the fibroblasts contain fewer CBs, SART3/
p110 was concentrated in every CB observed. In contrast to
the striking overlap between SART3/p110 and snRNPs in
CBs, only partial colocalization of SART3/p110 and sn-
RNPs was observed in the nucleoplasm (Fig. 1 A).
The survival of motor neuron protein (SMN) is involved
in the assembly of snRNPs in the cytoplasm (Fischer et al.,
1997; Massenet et al., 2002). In addition, SMN and associ-
ated gemin proteins are detected in the cell nucleus in struc-
tures termed gems (Liu and Dreyfuss, 1996). Gems often
overlap or are associated with CBs, depending on the cell
type (Carvalho et al., 1999; Young et al., 2000). The func-
tion of nuclear SMN is currently unknown, although roles
in splicing and transcription have been hypothesized (Pelliz-
zoni et al., 1998, 2001). Because a role for gems in snRNP
recycling has been proposed, we tested whether SART3/
p110 specifically localizes to gems in a HeLa cell line in
which gems are often separate from CBs. Double staining of
HeLa cells with anti-SART3/p110 and anti-SMN antibod-
ies (Fig. 2 A) revealed that SART3/CBs were overlapping or
adjacent to gems only 58% of the time (
 
n
 
 
 
 
 
 55 cells). Like
the HeLa cell line, WI-38 primary fibroblasts often con-
tained gems independent from CBs. We did not detect any
enrichment of SART3/p110 in gems in primary fibroblasts
(Fig. 2 B). Because 100% of CBs contain SART3/p110 (see
above), we conclude from this result that gems, per se, are
not sites of SART3/p110 accumulation.
To investigate the targeting of SART3/p110 to CBs, we
analyzed the role of coilin in SART3/p110 recruitment to
CBs. We compared the distribution of SART3/p110 in em-
bryonic fibroblasts derived from a wild-type mouse versus a
mouse in which both coilin alleles were disrupted (Tucker et
al., 2001). Wild-type mouse embryonic fibroblasts have sn-
RNPs, SMN, fibrillarin, and Nopp140 localized in CBs
(Tucker et al., 2001; Fig. 3). In embryonic fibroblasts de-
rived from the coilin knockout mouse, fibrillarin and
Nopp140 are accumulated in so-called “residual” CBs,
which fail to recruit snRNPs and SMN; snRNPs are distrib-
uted throughout the nucleoplasm, and SMN is concentrated
in separate gems (Tucker et al., 2001). Similar to our previ-
ous results, we found that SART3/p110 was detected in the
nucleoplasm and in CBs of coilin
 
 
 
/
 
 
 
 cells, labeled either by
anti–TMG cap, anti-fibrillarin, or anti-SMN antibodies
(Fig. 3, A, C, and E). In coilin
 
 
 
/
 
 
 
 cells, SART3/p110 was
distributed throughout the nucleoplasm with no detectable
concentration in residual CBs (Fig. 3 B) or gems (Fig. 3 D).
Double staining of coilin
 
 
 
/
 
 
 
 cells with anti–TMG cap and
SART3/p110 antibodies revealed the distribution of sn-
RNPs and SART3/p110 throughout the nucleoplasm and
never in the highly concentrated sites detectable in wild-type
cells (Fig. 3, compare E with F). Thus, coilin expression is
required for the recruitment of both snRNPs and SART3/
p110 to CBs.
Splicing largely occurs at transcription sites (for review see
Neugebauer, 2002). To test the possibility that SART3/
p110 is cotranscriptionally recruited to snRNPs, we labeled
nascent RNA with BrUTP and visualized labeled RNA
together with SART3/p110 (Fig. 4 A). Nucleoplasmic
SART3/p110 did not appreciably overlap with transcription
sites. During the course of these experiments, we noticed
that cells permeabilized under run-on conditions (see Mate-
rial and methods) exhibited a dramatic loss of SART3/p110
from CBs (compare Fig. 4 B with Fig. 1 B). We have further
investigated this phenomenon and found that snRNPs were
also largely extracted from CBs during run-on transcription
as revealed by TMG cap labeling (Fig. 4 C). In contrast,
run-on treatment did not affect the detection of coilin,
fibrillarin, or SMN in CBs and/or gems (Fig. 4 C). This sug-
Figure 2. SART3/p110 is not specifically localized in gems. SART3/
p110 and SMN, enriched in gems, were immunolocalized in (A) 
HeLa cells and (B) human primary fibroblasts WI-38. Examples of 
CBs are marked by arrowheads, gems by arrows. Inserts are magnified 
two times, and green (left), red (middle), and merged (right) signals 
are shown. Bar, 10  m.T
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gests that snRNPs and SART3/p110 are only weakly associ-
ated with CBs, compared with the apparently more stable
components, coilin, SMN, and fibrillarin.
The presence of U4 and U6 snRNAs (Carmo-Fonseca et
al., 1992; Matera and Ward, 1993) and SART3/p110 in
CBs indicates that CBs contain the substrates and at least
one factor required for U4/U6 snRNP assembly. To deter-
mine whether the U6 snRNA–associated LSm proteins that
promote U4/U6 annealing in vitro (Achsel et al., 1999) are
also present in CBs, we analyzed the distribution of two
members of the LSm complex. By immunofluorescence,
LSm4 was detected both in the cytoplasm and the nucleus
(Fig. 5, A and B). The cytoplasmic localization may repre-
sent LSm complexes involved in mRNA degradation (Bou-
veret et al., 2000; Tharun et al., 2000). In the nucleus,
LSm4 was detected throughout the nucleoplasm and con-
centrated in CBs (Fig. 5 A). Double staining of HeLa cells
with anti-LSm4 and anti–TMG cap antibodies revealed
complete overlap of both antigens in CBs but only partial
overlap in the nucleoplasm (Fig. 5 B). Similarly, LSm8
tagged with EYFP was mainly detected in the nucleoplasm
 
and in CBs (Fig. 5 C) where it colocalized with LSm4 (Fig.
5 D). Although LSm proteins participate in several distinct
complexes, including the 
 
Xenopus laevis
 
 U8 small nucleolar
RNP (Tomasevic and Peculis, 2002) and a cytoplasmic
mRNA degradation complex (Bouveret et al., 2000; Tharun
et al., 2000), it is likely that localization of LSm4 and LSm8
reflects the presence of the mature U6 snRNP in CBs.
The observations that SART3/p110, snRNPs, and LSm
proteins are concentrated in CBs (Figs. 1 and 5) and that sn-
RNP and SART3/p110 association with CBs is correlated
(Figs. 3 and 4) combine to suggest that SART3/p110 may
accumulate in CBs for the purpose of U4/U6 snRNP assem-
bly. However, an alternative hypothesis is that SART3/p110
is inactive and perhaps stored in CBs. To distinguish be-
tween these possibilities, we tested whether SART3/p110
concentration in CBs was affected by transcription activity
in the cell. It was previously shown that depleting the cell of
pre-mRNA by blocking RNA polymerase II activity leads to
a reduction in overall snRNP concentration in CBs (Carmo-
Fonseca et al., 1992). If SART3/p110 is stored in the CB,
one would expect SART3/p110 levels to remain constant or
even increase upon transcription inhibition. If, in contrast,
SART3/p110 in CBs is active in U4/U6 snRNP assembly,
then SART3/p110 levels in CBs should decrease when tran-
scription is inhibited.
To determine whether SART3/p110 concentration in
CBs is dependent on RNA synthesis, cells were treated with
the transcription inhibitor 
 
 
 
-amanitin. After treatment, all
cells had rounded splicing factor compartments (SFCs) la-
beled with SC-35 (Fig. 6, A and B), an indication of RNA
polymerase II inhibition (Carmo-Fonseca et al., 1992). Nei-
ther SART3/p110 nor LSm4 was enriched in SFCs. The lat-
ter result was unexpected, because other snRNPs (U1, U2,
U4, and U5) have been shown to concentrate in SFCs after
 
 
 
-amanitin treatment (Carmo-Fonseca et al., 1992; Blen-
cowe et al., 1993). After 
 
 
 
-amanitin treatment, two types of
coilin-positive CBs were observed: normal-looking CBs (in-
distinguishable from CBs in nontreated cells in size and
morphology) and enlarged “ring-shaped” CBs, as reported
previously (Carmo-Fonseca et al., 1992; Haaf and Ward,
1996; Frey et al., 1999). This change in CB morphology is
not likely to reflect cell death because 
 
 
 
95% of the cells
were viable, according to a standard viability test (see Mate-
rial and methods). In contrast to control untreated cells
(Figs. 1 and 5), we did not detect any specific enrichment of
SART3/p110 or LSm4 in any of the coilin-labeled CBs (Fig.
6, C and D). Quantitation of the fluorescence intensities
within normal-looking CBs relative to the nucleoplasmic
signal revealed that SART3/p110 levels in CBs decreased
threefold (P 
 
 
 
 0.0001) and LSm4 levels in CBs decreased
twofold (P 
 
 
 
 0.0001) after 
 
 
 
-amanitin treatment. These re-
sults indicate that SART3/p110 and LSm4 association with
CBs is transcription/splicing dependent and not likely due
to the storage of inactive molecules.
To determine how SART3/p110 is specifically localized
to CBs, we investigated the potential of isolated SART3/
p110 protein domains fused with EGFP to target CBs. Hu-
man SART3/p110 is composed of three major protein do-
mains, a repeat of seven HAT (half a TPR domain) motifs
followed by a nuclear localization signal, two RNA recogni-
Figure 3. SART3/p110 recruitment to CBs requires coilin. 
Mouse embryonic fibroblasts derived from control (coilin
 / ) or 
coilin knockout (coilin
 / ) mice were stained for SART3/p110 
together with (A and B) fibrillarin (Fib), (C and D) SMN, and (E and 
F) TMG cap. (A, C, and E) In control coilin
 /  cells, SART3/p110 
concentrates in CBs labeled by fibrillarin, SMN, and TMG cap 
(Tucker et al., 2001). (B, D, and F) In cells lacking functional coilin, 
SART3/p110 is distributed throughout the nucleoplasm and is not 
recruited to residual CBs labeled by fibrillarin (B) or gems labeled 
by SMN (D). No CBs were detected by TMG cap (F). Inserts are 
magnified two times, and red (left), green (middle), and merged 
(right) signals are shown. Bar, 5  m.T
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tion motifs (RRMs), and the highly conserved COOH-ter-
minal domain CT10 (Fig. 7 A; Bell et al., 2002; Rader and
Guthrie, 2002). The HAT domains and their related TPR
domains are present in a number of other RNA processing
factors and have been hypothesized to function in protein–
protein interactions (Preker and Keller, 1998; Zhou et
al., 2002). Recently, the SART3/p110 HAT domain was
shown to interact with the HIV-1 Tat protein (Liu et al.,
2002). The RRMs have been implicated in U6 snRNA
binding (Shannon and Guthrie, 1991; Bell et al., 2002),
and the CT10 domain likely mediates binding to the U6
snRNP via interaction with LSm proteins, as it does in yeast
(Rader and Guthrie, 2002). In two-hybrid assays, full-
length SART3/p110 interacted specifically with LSm7 but
not with LSm1, which is not present in the U6 snRNP. De-
letion of the CT10 domain reduced the two-hybrid interac-
tion twofold, suggesting that the CT10 domain contributes
to SART3/p110 binding to the U6 snRNP via LSm pro-
teins (unpublished data). We created several EGFP-tagged
proteins composed of specific SART3/p110 domains (Fig. 7
A). Note that each fusion protein diagrammed (except
N-TERM) was also produced with the EGFP tag at the NH
 
2
 
terminus, and the results were identical to those obtained
with the COOH-terminal–tagged constructs (unpublished
data), indicating that the protein localization results de-
scribed below are not due to the addition of the tags at the
COOH termini.
The full-length SART3/p110–EGFP (WT) revealed the
same distribution as endogenous SART3/p110 (Fig. 7 B,
WT; compare with Fig. 1); it localized to the nucleoplasm
and was concentrated in CBs, as judged by coilin staining.
Deletion of the highly conserved COOH-terminal domain
CT-10 (
 
 
 
CT10) or both CT-10 and the two RNA recogni-
tion motifs (
 
 
 
CT10
 
 
 
RRM) resulted in similar localization
patterns as full-length SART3/p110. In contrast, truncation
of the NH
 
2
 
-terminal portion of the protein containing seven
HAT repeats (
 
 
 
HAT) had strong effects on protein localiza-
tion. The 
 
 
 
HAT–EGFP protein was found in the nucleo-
plasm and concentrated in nucleoli, but was only weakly de-
tectable in CBs. Because EGFP conjugated to an NLS
(EGFP–NLS) was also concentrated in nucleoli and faintly
detectable in CBs, the simplest interpretation of the data is
that the concentration of 
 
 
 
HAT–EGFP in nucleoli and
weak detectability in CBs is nonspecific. To further investi-
gate the role of the NH
 
2
 
 terminus, we created a mutant con-
taining only the HAT domain and the endogenous NLS
(HAT). This construct was specifically targeted to CBs. In
contrast, the extreme NH
 
2
 
-terminal region of SART3/p110
(N-TERM), lacking the HAT domain and conjugated to
EGFP plus a heterologous NLS, was not specifically local-
Figure 4. SART3/p110 is depleted from CBs after nuclear run-on. 
(A) Cells were permeabilized using run-on conditions (see Materials 
and methods), and newly synthesized RNA was labeled by BrUTP 
and detected together with SART3/p110. Little colocalization of 
SART3/p110 with labeled RNA was detected. (B) Cells after run-on 
treatment were labeled for SART3/p110 and coilin. (B, inset) Repre-
sentative CB was magnified 3.5 times, and green (left), red (middle), 
and merged (right) signals are shown. (C) Control fixed cells 
(control) and cells after run-on (run-on) labeled with coilin together 
with TMG cap, fibrillarin (Fib), and SMN. For representative CBs, 
green (left), red (middle), and merged (right) signals are shown in 
the insets. Bars: (A and C) 5  m; (B) 10  m.T
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ized to CBs (compare N-TERM with EGFP–NLS localiza-
tions). Interestingly, the N-TERM mutant was not highly
concentrated in nucleoli, in contrast to EGFP–NLS alone.
Although the function of the extreme NH
 
2
 
-terminal region
of SART3/p110 is currently unknown, these results suggest
that it may interact with a nucleoplasmic component. We
conclude from this analysis that the HAT domain of
SART3/p110 is necessary and sufficient for the specific tar-
geting of SART3/p110 to CBs.
The highly conserved CT10 domain was previously
shown to interact with LSm proteins (Rader and Guthrie,
2002). To determine whether overexpression of SART3/
p110 mutants lacking the COOH-terminal region affects
the localization of endogenous SART3/p110 and/or
LSm4, we transfected HeLa cells with WT–, 
 
 
 
HAT–,
 
 
 
CT10–, and 
 
 
 
CT10
 
 
 
RRM–EGFP mutants and deter-
mined the localization patterns of endogenous SART3/
p110 and LSm4 by immunofluorescence (Fig. 8, WT–
EGFP and 
 
 
 
CT10
 
 
 
RRM–EGFP constructs shown only).
Quantitation of fluorescence intensities within CBs re-
lative to the nucleoplasm revealed that the localization
of endogenous SART3/p110 was significantly reduced in
 
 
 
CT10- and 
 
 
 
CT10
 
 
 
RRM-expressing cells, compared
with untransfected controls (Table I). This indicates that
both mutant proteins effectively compete for SART3/p110
binding sites within CBs. Moreover, if SART3/p110 plays
a role in U6 snRNP localization to CBs, then expression of
 
 
 
CT10 and/or 
 
 
 
CT10
 
 
 
RRM mutants may have domi-
nant negative effects on LSm4 localization in CBs. Indeed,
LSm4 concentration in CBs was significantly reduced
upon overexpression of 
 
 
 
CT10 or 
 
 
 
CT10
 
 
 
RRM mutants
by 
 
 
 
30% (Table I). The expression of WT–EGFP also in-
fluenced the concentration of LSm4 in CBs, but the effect
was less pronounced than in the case of 
 
 
 
CT10 or
 
 
 
CT10
 
 
 
RRM mutant (Table I). We noticed that CBs
were disrupted in some cells expressing high levels of
 
 
 
CT10 or 
 
 
 
CT10
 
 
 
RRM mutant (unpublished data).
The 
 
 
 
HAT–EGFP mutant, which is aberrantly localized
to nucleoli, did not show any effects on a localization of
LSm4 (unpublished data). These data suggest that SART3/
p110 plays a role in U6 snRNP targeting to CBs, largely
through the CT10 domain of SART3/p110.
Figure 5. U6 snRNP proteins LSm4 and LSm8 are enriched in 
CBs. HeLa cells stained for LSm4 and (A) coilin or (B) TMG cap. 
LSm4 is concentrated in CBs, where it colocalizes with TMG cap, 
whereas there is only partial overlap of LSm4 with TMG cap in the 
nucleoplasm. HeLa cells expressing LSm8–EYFP stained for (C) 
coilin or (D) Lsm4. LSm8 is diffusely distributed in the cell nucleus 
and concentrated in CBs. Examples of CBs are marked by arrow-
heads. For representative CBs, green (left), red (middle), and merged 
(right) signals are shown in the insets. Bar, 5  m.
Figure 6. SART3/p110 and LSm4 are depleted from CBs after 
transcription inhibition. (A and B) HeLa cells were treated with 
 -amanitin and stained for a marker of splicing factor compartments 
(SC-35) and (A) SART3/p110 or (B) LSm4. Enlarged, rounded-up 
splicing factor compartments indicate that inhibition of RNA 
polymerase II transcription was effective. (C and D) HeLa cells after 
 -amanitin treatment stained with anti-coilin antibody together with 
(C) anti-SART3/p110 or (D) anti-LSm4 antibodies. Two types of 
coilin-labeled structures were observed: normal-looking CBs 
(arrowheads) and enlarged ring-shaped CBs (arrows). Depicted 
areas containing CBs were enlarged two times (insets), and green 
(left), red (middle), and merged (right) signals are shown. Bars, 5  m.T
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Discussion
 
SART3/p110 is concentrated in CBs
 
The CB is a nuclear structure identified in many organisms
and cell lines, but little is known about its formation and
function (Matera, 1999; Gall, 2000; Ogg and Lamond,
2002). In this study, we show for the first time that
SART3/p110, a protein transiently associated with U4/U6
snRNP and with a defined function in the U4/U6 snRNP
assembly (Bell et al., 2002), is concentrated in CBs. In
HeLa cells, primary human fibroblasts, and mouse embry-
onic fibroblasts, we detected SART3/p110 by immunofluo-
rescence throughout the nucleoplasm and enriched in CBs,
where snRNPs were also highly concentrated. The localiza-
tion of SART3/p110 in CBs was confirmed by expression
of EGFP-tagged SART3/p110. Previous studies demon-
strated the nuclear localization of SART3/p110 (Gu et al.,
1998; Harada et al., 2001; Liu et al., 2002), but these ex-
periments did not specifically address whether SART3/
p110 was detectable in CBs. We did not find any signifi-
cant overlap of nucleoplasmic SART3/p110 with sites of
RNA synthesis, consistent with SART3/p110’s absence
from the U4/U6•U5 tri-snRNP and spliceosomes (Bell et
al., 2002; Rappsilber et al., 2002; Zhou et al., 2002) and
further suggesting that SART3/p110 is not recruited to sn-
RNPs cotranscriptionally.
To address how SART3/p110 is specifically targeted to
CBs, we constructed and expressed EGFP fusion proteins
containing distinct domains of SART3/p110. We found
that the SART3/p110 HAT domain with NLS is necessary
and sufficient to specifically localize EGFP-tagged constructs
to CBs. CstF77, a protein containing 10 HAT repeats, was
not concentrated in CBs (unpublished data), indicating that
the SART3/p110 HAT domain, and not all HAT domains
in general, can target proteins to CBs. Although all con-
structs containing the HAT domain were specifically tar-
geted to CBs, mutants lacking the COOH-terminal region
Figure 7. The NH2-terminal domain containing the HAT motifs targets SART3/p110 to CBs. (A) Wild-type (WT) SART3/p110 was 
conjugated to EGFP. Deletion mutants containing amino acids 1–950 ( CT10), 1–702 ( CT10 RRM), 581–963 ( HAT), and 119–702 (HAT) 
were conjugated to EGFP. The expression construct (N-TERM) encodes the NH2-terminal amino acids 1–127 fused to EGFP and a 
heterologous NLS signal. (B) All constructs including empty vector containing heterologous NLS (EGFP–NLS) were transiently expressed in 
HeLa cells and stained for coilin. Full-length protein as well as mutants containing the HAT domain accumulated in CBs (arrowheads). The 
 HAT protein and EGFP–NLS accumulated in nucleoli (arrows) and only weakly in CBs. The N-TERM mutant was detected throughout 
the nucleoplasm and slightly accumulated in nucleoli and CBs. The identification of nucleoli was verified by phase contrast microscopy 
(not depicted). Bar, 5  m.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
C
e
l
l
 
B
i
o
l
o
g
y
 
512 The Journal of Cell Biology 
 
|
 
 
 
Volume 160, Number 4, 2003
 
(
 
 
 
CT10, 
 
 
 
CT10
 
 
 
RRM, and HAT) showed less intense
signal than the full-length protein. Thus, although the
COOH-terminal half of SART3/p110 was not specifically
localized in CBs, the RRMs and/or CT-10 domain may en-
hance SART3/p110 retention in CBs by promoting binding
to snRNPs (Shannon and Guthrie, 1991; Rader and Guth-
rie, 2002).
Because SART3/p110 acts during snRNP assembly, we
wanted to test the hypothesis that gems, a nuclear structure
often associating with CBs, are the sites of snRNP regenera-
tion after splicing, as previously suggested (Pellizzoni et al.,
1998). In HeLa cells and primary human fibroblasts, where
gems are often separated from CBs, we found that SART3/
p110 was not concentrated in gems, as judged by double
immunofluorescence with anti-SMN (Fig. 2). Moreover,
mouse embryonic fibroblasts, which lack the CB-specific
protein coilin, also contain gems separate from residual CBs
(Tucker et al., 2001), and these gems lacked SART3/p110
as well (Fig. 3). Therefore, our data suggest that steps in U4/
U6 snRNP assembly or regeneration involving SART3/
p110 are unlikely to occur in gems.
Correlation of SART3/p110 and 
snRNP accumulation in CBs
The spliceosomal snRNPs are concentrated in CBs even
though CBs are not thought to be sites of pre-mRNA splic-
ing (Matera, 1999). Because newly synthesized snRNPs
transit CBs en route to the nucleoplasm (Sleeman and La-
mond, 1999; Sleeman et al., 2001), and because snRNPs are
depleted from CBs upon inhibition of transcription, a role
for CBs in snRNP assembly and regeneration has been pro-
posed (Carmo-Fonseca et al., 1992; Matera, 1999; Ogg and
Lamond, 2002). If this is true, then assembly factors like
SART3/p110 might interact with snRNPs in CBs. In this
study, three independent lines of evidence demonstrate a
correlation between SART3/p110 and snRNP accumulation
Figure 8. Expression of  CT10 RRM–EGFP mutant reduces the concentration of endogenous SART3/p110 and LSm4 in CBs. HeLa cells 
were transiently transfected with (A) WT–EGFP or (B and C)  CT10 RRM–EGFP constructs and, after fixation, immunostained with (A and C) 
anti-LSm4 or (B) anti-SART3/p110 antibodies. Note that anti-SART3/p110 antibodies were raised against the COOH terminus of SART3/p110 
and thus do not react with fusion proteins lacking the COOH-terminal part. Projections of five optical sections are shown. CBs in transfected 
cells are marked by arrowheads, in nontransfected cells by arrows. Examples of cytoplasmic accumulations of LSm4 are marked by double 
arrowheads. Bar, 10  m.T
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in CBs, suggesting that SART3/p110 associates with CBs in
a complex with snRNPs.
First, we show that SART3/p110 accumulation in CBs is
dependent on the expression of the CB-specific protein
coilin. In an embryonic fibroblast cell line established
from a coilin
 /  mouse, the CB components fibrillarin and
Nopp140 remain concentrated in so-called residual CBs,
which fail to recruit snRNPs (Tucker et al., 2001). We
found that SART3/p110 was detectable in the nucleoplasm
of these coilin
 /  cells but, like snRNPs, was absent from re-
sidual CBs (Fig. 3). Thus, coilin is required for snRNP as-
sembly into CBs (Bauer et al., 1994; Tucker et al., 2001)
along with factors involved in their metabolism, such as
SART3/p110.
Second, we show that SART3/p110 and snRNPs are de-
pleted from CBs by nuclear run-on treatment, in which the
activity of RNA polymerase II is preserved. In contrast,
fibrillarin, coilin, and SMN remained associated with CBs
after run-on treatment. The loss of SART3/p110 and sn-
RNPs under these conditions suggests that SART3/p110
and snRNPs associate weakly with CBs and are not stable
structural components of CBs. In light of recent efforts to
characterize the proteomic environment of a variety of sub-
nuclear structures (Mintz et al., 1999; Andersen et al., 2002;
Lam et al., 2002), these results indicate that at least some
important nuclear body components may be removed dur-
ing purification and therefore subsequently escape detection.
In this regard, it is noteworthy that a number of known nu-
cleolar proteins were indeed absent in the proteomic analysis
of isolated nucleoli (Andersen et al., 2002; Dundr and Mis-
teli, 2002).
Third, we show that SART3/p110 and LSm4, which are
normally concentrated in CBs (Figs. 1 and 5), are not specif-
ically concentrated in CBs after  -amanitin treatment, indi-
cating that SART3/p110 and LSm4 association with CBs is
transcription/splicing dependent. These results coincide
with previous findings (Carmo-Fonseca et al., 1992), which
describe the depletion of snRNPs from CBs after  -amani-
tin treatment. However, in contrast to other snRNPs, the
U6 snRNP component LSm4 and SART3/p110 were not
concentrated in SFCs after RNA polymerase II inhibition.
The dependence of SART3/p110 and snRNP accumulation
in CBs on transcription and splicing is consistent with the
hypothesis that CBs play an active role in snRNP metabo-
lism and do not represent storage sites for snRNPs or
SART3/p110.
CBs: sites of snRNP assembly?
The observations described here suggest that specific steps in
snRNP biogenesis, namely the binding of SART3/p110 to
its U4 and U6 snRNP substrates and possibly U4/U6 sn-
RNA annealing itself, occur in CBs. We propose a model in
Figure 9. A model for U4/U6 snRNP assembly in CBs. To form a 
functional U4/U6 snRNP, U4 and U6 snRNAs have to be annealed. 
The annealing occurs after their synthesis (and reimport from the 
cytoplasm in the case of U4 snRNP) as well as after each round of 
splicing. The U4/U6 snRNP subsequently interacts with U5 snRNP 
(yellow ball) to form U4/U6•U5 tri-snRNP. We propose that U4/U6 
snRNP assembly occurs in CBs. After splicing, the U6 snRNP is 
translocated to CBs as a single particle or in a complex with SART3/
p110, which promotes the U4 and U6 annealing. The assembly of 
the U4/U6 snRNP takes place in CBs, and SART3/p110 leaves the 
complex as U4/U6•U5 tri-snRNP is formed. U4/U6 snRNP assembly 
may also occur in the nucleoplasm (not depicted), which is likely 
the case in cells lacking morphologically defined CBs.
Table I. Effect of SART3/p110 mutant expression on concentration of the endogenous SART3/p110 and LSm4 in CBs
Overexpressed SART3/p110 protein Endogenous SART3/p110 Endogenous LSm4
Fluorescent intensity
(CB/nuc)   SD (n)
a
Significance
b Fluorescent intensity
(CB/nuc)   SD (n)
a
Significance
b
None 3.23   0.81 (166) NA 1.82   0.51 (124) NA
WT NA NA 1.58   0.40 (130) P   0.0011
 CT10 RRM 1.74   0.45 (105) P    10
 10 1.28   0.27 (157) P    10
 10
 CT10 1.65   0.49 (96) P    10
 10 1.26   0.27 (105) P    10
 10
HeLa cells were transiently transfected with WT–,  CT10–, and  CT10 RRM–EGFP constructs and immunostained for SART3/p110 or LSm4. Ratios of
SART3/p110 or LSm4 intensities in CBs with respect to their intensities in the nucleoplasm were determined. Data were collected from three independent
(two in case of  CT10 mutant) experiments. A t test was run with respect to control cells (None). Data were collected for WT/SART3 because anti-SART3/
p110 antibodies recognize the WT–EGFP protein. Cells expressing  CT10 or  CT10 RRM–EGFP exhibit a reduced level of SART3/p110 and LSm4 in CBs.
aRatio of average fluorescent intensity/pixel in CB and the nucleoplasm (nuc); n   number of CBs evaluated.
bP values determined from t test comparing fluorescent intensity ratio for the experimental data set versus control ratios (show in “None” row) for endoge-
nous SART3/p110 and LSm4.T
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which CBs are the sites of U4/U6 snRNP assembly (Fig. 9).
This may occur after snRNP nuclear import and/or after
each round of splicing, although direct evidence that sn-
RNPs cycle repeatedly through CBs is currently lacking.
This working hypothesis is consistent with the detection of
U4 and U6 snRNAs as well as TMG cap, Sm, and LSm pro-
teins in CBs (Carmo-Fonseca et al., 1991, 1992; Raska et
al., 1991; Matera and Ward, 1993) (Fig. 5), the latter indi-
cating that mature snRNPs are present (Matera, 1999). Im-
portantly, newly synthesized snRNPs imported from the cy-
toplasm first concentrate in CBs (Sleeman and Lamond,
1999; Sleeman et al., 2001). The model is further supported
by our data, which correlate snRNP and SART3/p110 asso-
ciation with CBs under the conditions of coilin knockout,
run-on treatment, and transcription inhibition (see above).
The fact that SART3/p110 associates with U6 and U4/U6
snRNPs only transiently and is not detectable in the U4/
U6•U5 tri-snRNP (Bell et al., 2002; Schneider et al., 2002)
is a key point in the proposal that the SART3/p110 concen-
tration in CBs reflects its function there.
The expression of mutant SART3/p110 lacking the CT10
domain or both CT10 and RRM domains reduced the levels
of endogenous SART3/p110 and LSm4 in CBs (Fig. 8; Ta-
ble I). These data indicate that endogenous SART3/p110
can be depleted from CBs by overexpression of mutant pro-
teins lacking the COOH-terminal region. These mutants
also have a dominant negative effect on LSm4 localization to
CBs, most likely due to the absence of the CT10 domain.
This observation is in agreement with the interaction ob-
served between the CT10 domain of Prp24, the yeast homo-
logue of SART3/p110, and LSm proteins (Rader and Guth-
rie, 2002) and further support the model that SART3/p110
is in a complex with the U6 snRNP in CBs. This observa-
tion satisfies one requirement of the proposal that U4/U6
snRNP assembly occurs in CBs (Fig. 9). Moreover, these re-
sults suggest that SART3/p110 plays a role in the targeting
of the U6 snRNP to CBs. In future studies, it will be impor-
tant to determine how the HAT domain specifies SART3/
p110 and U6 snRNP localization to CBs.
The presence of SART3/p110 in the nucleoplasm indi-
cates that SART3/p110 binding to its substrates and/or U4/
U6 annealing may also occur outside CBs. In cells lacking
morphologically defined CBs, U4/U6 assembly and recy-
cling likely takes place in the nucleoplasm, although it is
currently unknown whether other CB components, such as
nucleoplasmic coilin, also participate. The other possibility
is that besides snRNP regeneration, nucleoplasmic SART3/
p110 may be involved in other nuclear processes, as sug-
gested by others (Harada et al., 2001; Liu et al., 2002).
Splicing involves not only unwinding of U4 and U6 sn-
RNAs but also rearrangements within other snRNPs (Staley
and Guthrie, 1998). We speculate that CBs could be in-
volved in the assembly and/or recycling of snRNPs other
than U4/U6, for example the U4atac/U6atac snRNP, the
U4/U6•U5 tri-snRNP, and/or the U2 snRNP. This pro-
posal is supported by the recent finding that a 61-kD pro-
tein involved in formation of the U4/U6•U5 and the
U4atac/U6atac•U5 tri-snRNPs is also present in CBs
(Makarova et al., 2002; Schneider et al., 2002). Interest-
ingly, the U4atac/U6atac snRNP also contains LSm pro-
teins (Schneider et al., 2002), suggesting that SART3/p110
may also promote annealing of the U4atac/U6atac snRNP.
The concentration of these processes in CBs might represent
an efficient pathway for the assembly and recycling of tran-
scription and splicing factors in highly active cells with ele-
vated levels of transcription and splicing (Boudonck et al.,
1998; Gall et al., 1999; Pena et al., 2001).
Materials and methods
Cell lines and antibodies
HeLa cells, WI-38 primary fibroblasts (passages 16–18), and mouse embry-
onic fibroblasts 42 (coilin
 / ) and 26 (coilin
 / ) (Tucker et al., 2001) were
cultured in DME supplemented with 10% fetal calf serum, penicillin, and
streptomycin (GIBCO BRL). Rabbit anti-SART3/p110 antibodies were
raised against the COOH-terminal 16 amino acids (PKMSNADFAKLFL-
RKC) and affinity purified. The following additional antibodies were used:
mAb anti-coilin (5P10) (Almeida et al., 1998; provided by M. Carmo-Fon-
seca, Universidade de Lisboa, Lisboa, Portugal), mAb anti-SMN (2B1) (pro-
vided by G. Dreyfuss, University of Pennsylvania School of Medicine,
Philadelphia, PA; Liu and Dreyfuss, 1996), mAb anti-TMG (Oncogene Re-
search Products), mAb anti-fibrillarin (17C12) (Yang et al., 2001; provided
by K. Koberna and I. Ra ka, Institute of Experimental Medicine, Prague,
Czech Republic), mAb SC-35 (Fu and Maniatis, 1990), rat mAb anti-BrdU
(Harlan Sera Lab), and a rabbit antibody against LSm4 (provided by T.
Achsel and R. Luhrmann, Max Planck Institute for Biophysical Chemistry,
Göttingen, Germany; Achsel et al., 1999).
SART3/p110 cloning and protein tagging
The SART3/p110 gene was amplified from 293 cell RNA by RT-PCR in two
pieces, using DNA oligonucleotides A (GAATTCGCCACCATGGCGACT-
GCGGCCGAAACCTCGGC) and B (GCTATCCCAGAGTTCCCGGGC-
TTTCTGC) for the 5  portion (nt 1–1474) and C (GCAGAAAGCCCGG-
GAACTCTGGGATAGC) and D (GGAGATCTGACTTTCTCAGAAACA-
GCTTGGCAAAATCGGCATTGG) for the 3  portion (nt 1466–2889). Oli-
gonucleotide A contained an EcoRI restriction site as well as a Kozak
sequence, oligos B and C contained an XmaI site, and D contained a BglII
site. Reverse transcription was performed using MMLV reverse tran-
scriptase (GIBCO BRL), and PCR was performed using Pfu polymerase
(Stratagene) according to the manufacturer’s instructions. The two frag-
ments were sequentially ligated into the BglII, XmaI, and EcoRI sites of
plasmid pTYB4 (New England Biolabs, Inc.), and the entire EcoRI–BglII
fragment was subcloned into the EcoRI–BamHI sites of pBOS-H2BGFP
(BD Biosciences). Three independent bacterial transformants were se-
quenced (at the University of California San Francisco Biological Resource
Center), revealing two silent mutations (A127G and C2815T) as well as a
G507C mutation that results in a Gly→Ala change relative to the sequence
in GenBank/EMBL/DDBJ (accession no. D63879). Full-length SART3/p110
as well as deletion mutants ( CT10 aa 1–950;  CT10 RRM aa 1–702,
 HAT aa 581–963, and HAT aa 119–702) were amplified by Expand long
template PCR system (Roche) and cloned into EGFP-N1 and -C3 vectors
(CLONTECH Laboratories, Inc.) using BglII and EcoRI sites. The N-TERM
(aa 1–127) fusion construct was cloned using HindIII and KpnI sites into
EGFP-N2 vector (CLONTECH Laboratories, Inc.) containing at the COOH
terminus three tandem repeats of the NLS from simian virus large T-antigen
(gift of W. Haubensak, Max Planck Institute of Molecular Cell Biology and
Genetics). The NLS signal was cloned from EYFP-Nuc vector (CLONTECH
Laboratories, Inc.) using BsrGI and AflII sites.
The mouse LSm8 cDNA was obtained from R. Luhrmann and T. Achsel.
The mouse LSm8 protein has the same amino acid sequence as its human
homologue (Achsel et al., 1999). The full-length cDNA was amplified by
Expand long template PCR and cloned into EYFP-N1 vector using BglII and
KpnI restriction sites.
All fusion constructs were confirmed by sequencing. Fugene 6 (Roche)
was used for transfection of cells with the SART3/p110–EGFP and LSm8–
EYFP constructs.
Indirect immunofluorescence
Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) for 10 min, per-
meabilized for 5 min with 0.2% Triton X-100 (Sigma-Aldrich), and incu-
bated with the indicated antibodies. Secondary anti–mouse antibodies
conjugated with TRITC or FITC, anti–rat antibody conjugated with FITC,
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and anti–rabbit antibodies conjugated with TRITC, FITC, or Cy5 (Jackson
ImmunoResearch Laboratories) were used. Immunodetection of SART3/
p110 or LSm4 in cells expressing EGFP constructs was done 24–48 h after
transfection. Images were collected using the DeltaVision microscope sys-
tem (Applied Precision) coupled with Olympus IX70 microscope. Stacks of
25 z-sections with 200-nm z-step were collected per sample and subjected
to mathematical deconvolution (SoftWorx; Applied Precision). If not indi-
cated otherwise, the images shown here are single sections of the resulting
three-dimensional reconstructions.
Run-on transcription assay
Cells were permeabilized and RNA was labeled by BrUTP as previously de-
scribed (Wansink et al., 1993; Neugebauer and Roth, 1997). In brief, cells
were incubated in glycerol buffer (20 mM Tris-Cl, pH 7.4, 5 mM MgCl2,
25% glycerol, 0.5% PMSF, 0.5% EGTA) for 2 min at 37 C, overlaid with
BTB buffer (100 mM KCl, 50 mM Tris-Cl, pH 7.4, 5 mM MgCl2, 0.5 mM
EGTA, 25% glycerol, 2.5% PVA, and 0.1% Triton X-100) containing 0.5
mM ATP, GTP, and CTP and 0.2 mM BrUTP, incubated for 10 min at 37 C,
fixed with 4% paraformaldehyde, and processed for immunofluorescence.
Transcription inhibition
 -Amanitin treatment was performed as previously described (Carmo-Fon-
seca et al., 1992). HeLa cells were placed in fresh medium, and  -ama-
nitin (Sigma) was added to a final concentration of 50  g/ml. Cells were
incubated for 5 h and prepared for immunofluorescence as described
above. To test cell viability after  -amanitin treatment, the dye FM 4–64
(Molecular Probes) was added to culture medium (final concentration 16
nM). The dye incorporation into living cells was observed after 10 min and
compared with untreated control cells.
Measurement of fluorescence intensities
Fluorescence intensities were quantified with MetaVue software (Universal
Imaging Corp.) using deconvolved images (see above). The optical sections
were merged, and the intensities in random regions of the nucleoplasm di-
vided by the region area were taken as the values to which the intensities
within the CBs were compared. CB area was defined by SART3/p110–
EGFP constructs or by coilin labeling; intensities of SART3/p110 or LSm4
were measured within the CB and divided by the CB area. Data were col-
lected from 20–50 normal-looking CBs (Fig. 6) after  -amanitin treatment
and CBs in control cells, and 100–160 CBs in cells expressing different
SART3/p110–EGFP mutants or control untransfected cells (Table I).
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